Christina, there is something "grossly" (pardon the pun) wrong with the table in the MaxCyte story. (1) If, as you say, gross margins are 89%, then the gross profits in the table are way off, and (2) net margins at a constant 3% mean either (a) the business does not scale (I find this unlikely), or (2) someone has scaled "fixed" costs like GS&A, R&D as if they were variable.
What % of revenue comes from non gene editing applications ?
Christina, there is something "grossly" (pardon the pun) wrong with the table in the MaxCyte story. (1) If, as you say, gross margins are 89%, then the gross profits in the table are way off, and (2) net margins at a constant 3% mean either (a) the business does not scale (I find this unlikely), or (2) someone has scaled "fixed" costs like GS&A, R&D as if they were variable.
I like your work, though! Martin J. Monroe, PhD
Is there any conceivable path to profitability?